Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | QDPR | P09417 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 4/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4554358 | 0.91 | SMN1; SMN2 (0.43) | SMN1; SMN2QDPRHSD17B10ESR1TGFBR1 | |
| SCHEMBL5392280 | 0.71 | — | — | |
| SCHEMBL14008437 | 0.68 | GAA (0.36) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL20392266 | 0.67 | SMN1; SMN2 (0.51) | SMN1; SMN2QDPRHSD17B10ESR1TGFBR1 | |
| SCHEMBL7033604 | 0.66 | SMN1; SMN2 (0.50) | SMN1; SMN2QDPRHSD17B10ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL8476099 | 0.66 | SMN1; SMN2 (0.97) | SMN1; SMN2QDPRHSD17B10ESR1ESR2 | |
| SCHEMBL24839989 | 0.62 | SMN1; SMN2 (0.46) | SMN1; SMN2QDPRHSD17B10ESR1ESR2 | |
| SCHEMBL5077540 | 0.62 | SMN1; SMN2 (0.46) | SMN1; SMN2QDPRHSD17B10ESR1ESR2 | |
| SCHEMBL10828923 | 0.61 | QDPR (0.56) | SMN1; SMN2QDPRESR1ESR2AR | |
| SCHEMBL2720984 | 0.58 | ESR1 (0.56) | SMN1; SMN2QDPRHSD17B10ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137193-B1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI SA (FR) | 2017-08-09 | — | — | EP | disclosed |
| US-8642603-B2 | Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof | SANOFI (FR) | 2014-02-04 | — | — | US | disclosed |
| US-20100075994-A1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2010-03-25 | — | — | US | disclosed |
| CN-101675060-A | Substituted dihydro and tetrahydro oxazolopyrimidinones, their preparation and use | SANOFI AVENTIS | 2010-03-17 | — | — | CN | disclosed |
| EP-2137193-A2 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | Sanofi-Aventis (FR) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008112483-A2 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075994-A1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | GRM2, GRM1, GRIN2C | SMN1; SMN2 728/4885QDPR 69/4885HSD17B10 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.